Tempus AI's COO Ryan Fukushima sells shares worth $792,191

Published 09/01/2025, 08:26 am
TEM
-

Ryan Fukushima, the Chief Operating Officer of Tempus AI, Inc. (NASDAQ:TEM), recently sold a significant portion of his holdings in the company. According to a filing with the Securities and Exchange Commission, Fukushima sold shares totaling $792,191. These transactions occurred on January 7, with the sale prices ranging from $38.98 to $41.50 per share. The stock has shown strong momentum recently, posting a 15.15% gain over the past week. According to InvestingPro analysis, TEM is currently trading below its Fair Value.

Following these sales, Fukushima retains direct ownership of 982,442 shares of Tempus AI. Additionally, he holds indirect ownership of 131,893 shares through the Ryan Fukushima Irrevocable Family Trust and 150,000 shares by his spouse. The sales were conducted under a Rule 10b5-1 trading plan, which was adopted on June 14, 2024. While the company trades at a high Price/Book multiple of 109.86x, it maintains strong liquidity with a current ratio of 2.69. InvestingPro subscribers can access 7 additional key insights about TEM's financial health and valuation metrics.

In other recent news, Tempus AI has been the subject of various financial adjustments following its recent earnings report. Piper Sandler increased the company's price target from $40 to $70, maintaining a Neutral rating. The revised price target does not account for potential impacts from Tempus AI's acquisition of Ambry Genetics. Similarly, Stifel downgraded Tempus AI's stock from Buy to Hold, but increased the price target to $65, while Needham raised its stock price target to $56, sustaining its Buy rating.

The acquisition of Ambry Genetics by Tempus AI is viewed as a strategic move with potential for significant opportunities in data and applications over time. Tempus AI has also partnered with Avacta Therapeutics to utilize AI in advancing oncology drug development.

The company's Tempus ECG-AF device, which employs artificial intelligence to identify patients at higher risk of atrial fibrillation/flutter, recently received FDA clearance. These developments highlight Tempus AI's continued efforts in expanding its capabilities and partnerships in the AI sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.